Abstract
The efficacy of nifedipine in the prevention of post-infarction morbidity and mortality was evaluated in a double-blind clinical trial of 2276 survivors of acute myocardial infarction recruited from the cardiac departments of 14 Israeli hospitals. The patients were randomized to either nifedipine 30 mg day−1 or placebo between 7 and 21 days after their hospitalization for the acute event. Baseline characteristics of patients in each group were virtually identical for most pertinent variables. Mortality during an average 10-month follow-up period was 5.7% in the placebo group and 5.8% among those receiving nifedipine. Nonfatal recurrent myocardial infarction occurred in 4.8% and 4.4% of placebo and nifedipine patients, respectively. Administration of nifedipine according to the protocol used in the present study had no effect on cardiac events in survivors of acute myocardial infarction.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call